Tandem Diabetes Care (TNDM) Projected to Release Quarterly Earnings on Thursday

Key Points

• Tandem Diabetes Care is expected to report Q3 2026 results after market close on November 5, with analysts forecasting a loss of $0.2453 per share and revenue of $265.85 million.
• In its prior quarter, the company reported a $0.31 per-share loss, slightly beating estimates, while revenue rose 5.8% year over year to $254.56 million. Analysts project a $0.66 per-share loss for the full fiscal year.
• Shares opened at $19.68, and analysts have a consensus “Hold” rating with an average price target of $27.08; the stock has traded between $12.26 and $29.65 over the past year.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Tandem Diabetes Care to announce earnings of ($0.2453) per share and revenue of $265.85 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its earnings results on Thursday, August 6th. The medical device company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.01. The firm had revenue of $254.56 million for the quarter, compared to analyst estimates of $254.99 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.78) EPS. On average, analysts expect Tandem Diabetes Care to post ($0.66) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $19.68 on Thursday. The firm has a 50 day moving average of $18.16 and a 200-day moving average of $18.97. The stock has a market capitalization of $1.37 billion, a PE ratio of -21.16 and a beta of 1.66. The company has a current ratio of 3.18, a quick ratio of 2.65 and a debt-to-equity ratio of 4.62. Tandem Diabetes Care has a 12 month low of $12.26 and a 12 month high of $29.65.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TNDM. UBS Group assumed coverage on Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a "neutral" rating and a $18.00 target price on the stock. Citigroup cut their price objective on Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. Royal Bank Of Canada restated an "outperform" rating and set a $26.00 price objective (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tandem Diabetes Care in a report on Tuesday, September 8th. Finally, William Blair assumed coverage on Tandem Diabetes Care in a research report on Friday, August 21st. They issued an "outperform" rating for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Hold" and an average price target of $27.08.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company's products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem's product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.